News coverage about Sangamo Therapeutics (NASDAQ:SGMO) has been trending somewhat positive on Sunday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Sangamo Therapeutics earned a media sentiment score of 0.11 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 46.2486793418607 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Here are some of the news stories that may have impacted Accern Sentiment’s rankings:
- Sangamo Therapeutics Shows Rising Price Performance With Jump To 85 RS Rating (investors.com)
- CRISPR Science and Stocks: Knowing Enough to Invest (msn.com)
- Why Sangamo Therapeutics Stock Is Spiking Today (finance.yahoo.com)
- Traders Are Still Finding Plenty of Stocks That They Want to Buy (finance.yahoo.com)
- Sangamo Therapeutics (SGMO) Now Covered by Bank of America (americanbankingnews.com)
Sangamo Therapeutics opened at $16.50 on Friday, MarketBeat.com reports. Sangamo Therapeutics has a twelve month low of $8.00 and a twelve month high of $27.50. The company has a debt-to-equity ratio of 0.14, a quick ratio of 4.78 and a current ratio of 4.78. The company has a market capitalization of $1.64 billion, a PE ratio of -23.57 and a beta of 2.89.
Several research analysts have issued reports on SGMO shares. BidaskClub lowered Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, March 17th. Zacks Investment Research lowered Sangamo Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, May 10th. Bank of America started coverage on Sangamo Therapeutics in a report on Wednesday. They issued a “buy” rating and a $24.00 price target on the stock. Barclays reiterated a “buy” rating and issued a $30.00 price target on shares of Sangamo Therapeutics in a report on Sunday, February 25th. Finally, Wedbush reiterated a “hold” rating and issued a $8.00 price target on shares of Sangamo Therapeutics in a report on Tuesday, March 13th. One analyst has rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the company. Sangamo Therapeutics presently has an average rating of “Buy” and a consensus target price of $22.00.
In other news, VP Curt A. Herberts III sold 8,163 shares of the firm’s stock in a transaction that occurred on Friday, April 13th. The stock was sold at an average price of $20.00, for a total value of $163,260.00. Following the transaction, the vice president now owns 22,788 shares in the company, valued at $455,760. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Steven J. Mento sold 7,215 shares of Sangamo Therapeutics stock in a transaction on Monday, April 2nd. The stock was sold at an average price of $18.40, for a total value of $132,756.00. The disclosure for this sale can be found here. Insiders sold 47,656 shares of company stock worth $844,303 in the last 90 days. Corporate insiders own 1.20% of the company’s stock.
About Sangamo Therapeutics
Sangamo Therapeutics, Inc focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.